Drugs / Allogeneic natural killer cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00625729 | Jan 2008 → Dec 2009 | leukemia, lymphoma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00652899 | Mar 2008 → Aug 2009 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic natural killer cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00652899 ↗ |
| Modality | Cell therapy | “Patients receive aldesleukin-activated haploidentical NK cells IV over less than 1 hour on day 0.” NCT00625729 ↗ |
| Route | Intravenous | “Patients receive aldesleukin-activated haploidentical NK cells IV over less than 1 hour on day 0.” NCT00625729 ↗ |